Fast Track is being discussed for Anktiva in lung cancer. Now it's all happening fast.
Immunitybio Acciones Foro
StockStockISIN: US45256X1037
Ticker: IBRX
US45256X1037
IBRX
Debate sobre IBRX
Puestos
136Lun·
$IBRX (-2,88 %) It's getting nice and slow! There are now also very positive data on the treatment of lung cancer.
IBRX will really shake up current cancer treatment methods.
44
1 Comentario6Lun
the company was under the radar and oversold for a long time due to the CRL last year. After the long-awaited approval, it still hasn't leaked out what this event means for the future of cancer therapy. The media is not reporting on it, so there is no hype. If a partnership with Merck is announced (or another pharmaceutical giant), it will soon be leaked to the masses. FYI: Anktiva has a 71% success rate in the treatment of bladder cancer (WITHOUT adverse events), compared to Merck's Keytruda, the current standard therapy, with only 42% and sometimes severe side effects and a shorter duration of action
•
22
•6Lun·
News: $IBRX (-2,88 %) US FDA approves bladder cancer therapy from ImmunityBio!
Very positive for the rest of the pipeline ... lets go!
1Año·
Has anyone read news about $IBRX (-2,88 %) or knows what is going on? Almost 300% in one month.
11
11 Comentarios„NATIONAL MULTICENTER TRIAL OPENS TO STUDY IMMUNITYBIO'S TRI-AD5 CANCER
VACCINES PLUS N-803 TO PREVENT CANCER IN PEOPLE WITH LYNCH SYNDROME“ - Reuters
VACCINES PLUS N-803 TO PREVENT CANCER IN PEOPLE WITH LYNCH SYNDROME“ - Reuters
•
22
•2Año·
Verkauf für Umschichtung
1 Comentario
2Año
Why did you sell at this point? Uptrend on short timeframe is still in tact. The saucer is only just being filled and resistance is still to come 🙂 In addition, a cooperation is to be published ... @ShovelStocks certainly knows more about it.
•
11
•2Año·
Tranche 3 of 3
Cost price lowered to 5.00 euros. The position will no longer be expanded regardless of what happens, as the position is still speculative.
@ShovelStocks because of me the FDA can allow it NOW xD
11
3 Comentarios2Año
Ditto... was able to lower the purchase price to € 4.68 and now hold my manageable position of 250 shares.
•
11
•Valores en tendencia
Principales creadores de la semana